In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Leuprolide | Synthetic analog Triptorelin (Trelstar, Decapeptyl) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 707 | 1,338 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 167 (167 in people) | 164 (160 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 393 · 85 active117 more mention it but do not test it | 207 · 44 active104 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Leuprolide acetate for depot suspension says: “Selected three-month depot formulation for advanced prostate cancer”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Leuprolide | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 19616630 | 782599171 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
| Adverse eventsWhole body | 112112 | 105105 |
|---|
| Tumor growthReproductive and sexual health | 70682 | 524624 |
|---|
| Bone and jointMusculoskeletal | 2525 | 74713 |
|---|
| PainSkin and wound | 3535 | 1414 |
|---|
| PharmacokineticsPharmacology | 341915 | 19136 |
|---|
| Surgical outcomesReproductive and sexual health | 1010 | 2020 |
|---|
| Receptor activity and mechanismReproductive and sexual health | 1459 | 7425715 |
|---|
| MortalityCancer | 1313 | 1212 |
|---|
| Body weightMetabolic and weight | 541 | 17161 |
|---|
| Growth hormone and IGF-1Reproductive and sexual health | 1394 | 121011 |
|---|
| Sexual functionReproductive and sexual health | 14122 | 761 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Leuprolide differs from Gonadorelin at 2 positions.
What is different
Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 393 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novartis Pharmaceuticals3,246 participants30 Nov 2016 to 9 Nov 2022
Breast Cancer
Radiation Therapy Oncology Group2,028 participantsOct 1994 to 14 May 2018
Prostate Cancer
SWOG Cancer Research Network1,939 participants12 Sept 2013 to est. Jan 2030
Breast Cancer
117 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024
Breast Cancer
Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)
Prostate Cancer
104 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Leuprolide | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| MortalityCancerCompared as: value in the arm that got the peptide, in % | 90.5% Survival rate Dose studied: 7.5 mg every 28 days9 months (253 days)n = 2842003 | 97% Survival Dose studied: 3.75 mg9 monthsn = 2842003 |
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 58.5% Pregnancy rate n = 1292005 | 22.7% Pregnancy rate Placebo: 22.1% Dose studied: 0.1 mgSingle injectionn = 3442010 |
| Surgical outcomesReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 80% Vaginal hysterectomy 2 monthsn = 901994 | 53% Vaginal procedure indication · triptorelin 32/60 12 weeksn = 1231998 |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | −38.4% Median fibroid volume change single injection; 12-week pretreatment periodn = 552020 |
90.5%
Survival rate
Dose studied: 7.5 mg every 28 days9 months (253 days)n = 2842003
97%
Survival
Dose studied: 3.75 mg9 monthsn = 2842003
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Leuprolide | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| PainReproductive and sexual healthCompared as: difference from placebo, in none | No comparable result 29 randomized-trial results measure it in another way or another unit. | 1 none P value Dose studied: triptorelin depot-3.753 monthsn = 54 |
21 to 97%
Nodule volume reduction
Dose studied: 3.75 mg every 28 days, four administrationsn = 252007
58.5%
Pregnancy rate
n = 1292005
22.7%
Pregnancy rate
Placebo: 22.1%
Dose studied: 0.1 mgSingle injectionn = 3442010
80%
Vaginal hysterectomy
2 monthsn = 901994
53%
Vaginal procedure indication · triptorelin 32/60
12 weeksn = 1231998
−38.4%
Median fibroid volume change
single injection; 12-week pretreatment periodn = 552020
21 to 97%
Nodule volume reduction
Dose studied: 3.75 mg every 28 days, four administrationsn = 252007
| Organ injuryReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −50% Lesion extent reduction · Shown as a change. The study reports a lesion extent reduction of this size. 6 monthsn = 491998 |
|---|
| Cognition and memoryNervous system and cognitionCompared as: value in the arm that got the peptide, in points | 0.18 points ADAS-Cog mean decline · high-dose leuprolide (22.5 mg), AChEI subgroup Placebo, AChEI subgroup: 3.3 points Dose studied: 22.5 mg48 weeksn not reported2015 | No randomized trial result 4 results from other study designs. |
|---|
| Adverse eventsReproductive and sexual healthCompared as: difference from placebo, in percentage points | No comparable result 64 randomized-trial results measure it in another way or another unit. | −14.7 percentage points Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size. Dose studied: 0.1 mg, single dosen = 1442018 |
|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | 11.1% Fat mass increase 12 monthsn = 522004 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
|---|
| Bone and jointEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | −2.5% Bone mineral density change · leuprolide, baseline to 12 months 12 monthsn = 522004 | No comparable result 16 randomized-trial results measure it in another way or another unit. |
|---|
No comparable result
29 randomized-trial results measure it in another way or another unit.
1 none
P value
Dose studied: triptorelin depot-3.753 monthsn = 542008
No comparable result
1 randomized-trial result measure it in another way or another unit.
−50%
Lesion extent reduction · Shown as a change. The study reports a lesion extent reduction of this size.
6 monthsn = 491998
0.18 points
ADAS-Cog mean decline · high-dose leuprolide (22.5 mg), AChEI subgroup
Placebo, AChEI subgroup: 3.3 points
Dose studied: 22.5 mg48 weeksn not reported2015
No randomized trial result
4 results from other study designs.
No comparable result
64 randomized-trial results measure it in another way or another unit.
−14.7 percentage points
Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size.
Dose studied: 0.1 mg, single dosen = 1442018
11.1%
Fat mass increase
12 monthsn = 522004
No comparable result
2 randomized-trial results measure it in another way or another unit.
−2.5%
Bone mineral density change · leuprolide, baseline to 12 months
12 monthsn = 522004
No comparable result
16 randomized-trial results measure it in another way or another unit.